ANTI-TUMOR-THERMAL TERPENOID PHARMACEUTICAL COMPOSITION WITH ANGIOGENESING-INHIBATING ACTION

摘要

The invention relates to medicine and the pharmaceutical industry and relates to an agent for treating diseases associated with impaired regulation of angiogenesis, in particular to a method for treating oncological diseases of various origins, by inducing inhibition of angiogenesis against a background of direct antitumor, antirecurrent and antimetastatic effects, as well as concomitant activation endogenous apoptosis system. The invention is implemented using a new oral dosage form - Abisilin, containing ingredients belonging to the class of natural terpene compounds (isoprenoids) obtained from conifers of the Pinaceae family, including: sequiterpenoids (3-6%), neutral diterpenoids (11-15%), diterpenic acids (23-28%), triterpenic acids (8-16%), unsaturated and saturated fatty acids (0.1-0.3%), phenolic compounds (0.1-0.2%) and the rest are monoterpenoids, with a content of boron acetate of at least 10.0% of the total composition of terpenes. It is assumed that the use of the new oral dosage form Abisilin, for the substance of which immunomodulating, antibacterial, anti-inflammatory, analgesic, wound healing and other pharmacologically significant actions are known, as well as the absence of contraindications, toxic effects and the possibility of complex use with various agents, implements a new therapeutic approach and will increase the effectiveness treatment of cancer and many other diseases associated with the violation of the processes of angiogenesis.